Flips

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Novartis' migraine drug gets EMA approval

  pharmatimes.com

  Aimovig becomes Europe’s first treatment specifically designed to prevent migraine

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Pfizer CEO on what happened after Trump tweeted

  CNBC - Meg Tirrell

  Before he even spoke to the president, Pfizer CEO Ian Read said he knew the best move was to defer the drug giant's early July price increases; a …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Kyoto team pits iPS cells against Parkinson's disease

  japantimes.co.jp - No Author

  A Kyoto University research team said Monday it will begin a clinical test this week using induced pluripotent stem cells to treat Parkinson’s …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Dementia

  Highly Anticipated Data On Would-Be Alzheimer's Drug Raises Hope And Questions

  Forbes - Ellie Kincaid

  How does Biogen Chief Medical Officer Al Sandrock feel after the curtain was lifted on clinical trial data of the experimental Alzheimer’s drug his company is developing with Japanese drugmaker Eisai?

• 

  Miguel Tovar

  flipped into Pharma readings

  

  GSK bets $300 million on genetics as CEO plays down break-up talk

  Reuters - Ben Hirschler

  LONDON (Reuters) - GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a of

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Eisai, Biogen battered by controversy over PhII Alzheimer's study after posting positive results

  endpts.com - John Carroll

  At first blush, Ei­sai and Bio­gen post­ed the kind of promis­ing da­ta for BAN2401 that might have over­come some doubts about its po­ten­tial as a …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  23andMe

  23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs

  Forbes - Matthew Herper

  GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and profits equally, and Glaxo will a

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Novartis's Cultural Revolution Will Be AI-Enabled, Desk-Free

  Bloomberg - James Paton

  When sales staff at drugmaker Novartis AG wake up each morning, an artificial-intelligence program will soon tell them how best to organize their …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Glaxo’s New Research Chief Loves Big Pharma. Now He Has To Fix It

  Forbes - Matthew Herper

  It might seem an odd, even brusque question, especially when asked to the CEO of a major pharmaceutical company by a recently hired employee. But it’s how Hal Barron, the new chief scientific officer GlaxoSmithKline,

• 

  Miguel Tovar

  flipped into Pharma readings

  https://www.nytimes.com/2018/07/23/us/politics/trump-drug-prices.html

  Miguel Tovar

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Top Alzheimer’s researchers hope that near-100 dementia drugs in trials are moving closer to a breakthrough

  CNBC - Kelly Song

  The search for an Alzheimer’s disease cure has been dogged by pharmaceutical failures, but a network of the world’s top dementia scientists released …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Investing

  Novartis to Pay as Much as $1 Billion for Skin Drug Rights

  Bloomberg - Thomas Mulier

  Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Novartis shelves US price increases | Financial Times

  Financial Times - Ralph Atkins, Sarah Neville

  Swiss drugmaker Novartis has announced that it will shelve price increases for medicines in the US after criticism of the sector from President Donald Trump over rising costs. “We have voluntarily pulled

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases – Bloomberg

  Bloomberg

  Novartis AG Chief Executive Officer Vas Narasimhan talks about U.S. drug pricing, government health-care policy and plans to spin off the Swiss …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  J&J beats quarterly expectations on drug sales surge, shares jump

  Reuters - Manas Mishra

  (Reuters) - Johnson & Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade,

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Investing

  Novartis Blockbuster Drug Rebounds, Easing Generics Pressure

  Bloomberg - James Paton

  Novartis CEO Vas Narasimhan discusses drug pricing, government policy and plans to spin off the Alcon eye-care unit. Novartis AG saw sales of one of …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered

  CNBC - Angelica LaVito

  Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Bill Gates

  Bill Gates Announces Further Investment In Alzheimer's Research, Taking On Disease Detection

  Forbes - Michela Tindera

  Microsoft cofounder Bill Gates revealed more of his plan to invest in Alzheimer's disease research on Tuesday. He along with fellow billionaire Leonard Lauder, the Dolby family, the Charles and Helen Foundation

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Big Pharma’s Metabolism Is Slowing Down

  Bloomberg Opinion - Max Nisen

  Investors need to face the fact that the sector’s best growth days may be behind it. Investors need to face the fact that the sector’s best growth days may be behind it. The biggest players in pharma biotech

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Drugmakers will think twice on price increases after Trump's Pfizer skirmish, says analyst

  CNBC

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area

  Bloomberg - Aziza Kasumov

  Novartis AG will shut down its antibacterial and antiviral research operations in the San Francisco Bay area and cut about 140 jobs, joining other …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Pfizer delays drug price hikes after talking with Trump

  Reuters - Yasmeen Abutaleb, Michael Erman

  WASHINGTON/NEW YORK (Reuters) - Pfizer Inc (PFE.N) said on Tuesday it was deferring drug price increases for no more than six months after the company’s chief executive officer had an extensive conversation

• 

  Miguel Tovar

  flipped into Pharma readings

  China vows to accelerate cancer drug price cuts

  

  China vows to accelerate cancer drug price cuts | Financial Times

  Financial Times - Tom Hancock, Wang Xueqiao

• 

  Miguel Tovar

  flipped into Pharma readings

  

  The dementia dilemma

  pharmatimes.com

  The failure of several Alzheimer’s drug trials in the past year has dampened, but not destroyed, hopes for a cure To the patients desperately waiting …

• 

  Miguel Tovar

  flipped into Pharma readings

  This story was written by Matthew Herper and Michela Tindera. The indictment of Theranos founder Elizabeth Holmes, and the barrage of shocking details about her company unearthed by John Carreyrou in …

  

  Venture Capital

  Theranos? Whatever. Healthcare Startups Have Raised $15 Billion So Far This Year

  Forbes - Matthew Herper

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

  Reuters - Ben Hirschler

  LONDON (Reuters) - AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. FILE PHOTO:

• 

  Miguel Tovar

  flipped into Pharma readings

  

  The Brain

  Biogen And Eisai Say Alzheimer's Drug A Success, Reversing Earlier Result

  Forbes - Matthew Herper

  A complicated new clinical trial could give some hope to Alzheimer's patients and investors in drug companies. But there are lots of devilish details. Drugmakers Biogen and Eisai said the top dose of experimental

• 

  Miguel Tovar

  flipped into Pharma readings

  

  A Risky Drug Approval Lesson

  The Wall Street Journal. - The Editorial Board

  What the FDA can learn from progress against muscular dystrophy. Some welcome news arrived recently for boys with a condition called Duchenne muscular dystrophy. A new therapy is showing promising results,

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Amazon could start selling discounted meds to cash payers as soon as the PillPack deal closes

  CNBC - Christina Farr

  Now that Amazon has snapped up internet pharmacy PillPack for around $1 billion in cash, how long will it take before consumers can rely on the …

• 

  Miguel Tovar

  flipped into Pharma readings

  

  Sanofi beefs up diabetes pipeline to retrieve success

  Reuters - Matthias Blamont

  PARIS (Reuters) - Sanofi sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance,